Yesterday, CMS announced the Manufacturer Request for Applications (RFA) for its Cell and Gene Therapy (CGT) Access Model. The CGT model aims to improve the lives of Medicaid beneficiaries with severe and rare diseases. States will work together with manufacturers selected by CMS to improve access to gene therapy treatments for sickle cell disease, a genetic blood disorder disproportionately impacting Black Americans.